Related Experiment Video
Updated: Jun 9, 2026
08:04
Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
Published on: June 6, 2025
Ethical Considerations in Carbamazepine Pharmacogenomics Testing.
Madeline Yuzwa1, Rachel Conrad Bracken2
1Department of Pharmacy, Northeast Ohio Medical University.
Innovations in Pharmacy
|June 8, 2026
Summary
Pharmacogenomic testing for carbamazepine faces ethical challenges. Current FDA guidelines are insufficient, necessitating an updated framework for privacy, access, and informed consent in personalized medicine.
Area of Science:
- Pharmacogenomics
- Personalized Medicine
- Bioethics
Background:
- Carbamazepine is a key anticonvulsant with pharmacogenomic implications.
- Personalized medicine aims to tailor treatments using genetic information.
- Existing regulatory guidelines for pharmacogenomic testing have limitations.
Purpose of the Study:
- To critically examine the ethical implications of carbamazepine pharmacogenomic testing.
- To assess the adequacy of current FDA guidelines.
- To propose an improved ethical framework for implementation.
Main Methods:
- Comprehensive literature review.
- Ethical analysis of pharmacogenomic testing.
- Evaluation of FDA guidelines for carbamazepine.
Main Results:
- Current FDA guidelines inadequately address patient privacy, autonomy, equitable access, and genetic discrimination.
- Key ethical concerns in pharmacogenomic testing require more robust oversight.
- An updated framework is needed to balance clinical utility and ethical considerations.
Conclusions:
- Enhanced guidelines are crucial for the ethical implementation of carbamazepine pharmacogenomic testing.
- Recommendations include equitable access, comprehensive education, robust data privacy, and culturally aware counseling.
- Interdisciplinary collaboration is essential for advancing ethical pharmacogenomics.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...